BioSpace News Archive

Xeno Biosciences Inc. announced a change in executive leadership as of September 2023, and the completion of an additional financing round in February of 2024.

Vancouver, British Columbia--(Newsfile Corp. - April 17, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today reported its financial and operational results for the year ended December 31, 2023.

According to Nova One Advisor, the global point of care diagnostics market size was accounted for USD 44.25 billion in 2023 and it will increase to around USD 80.75 billion by 2033 with a CAGR of 6.2% from 2024 to 2033.

According to recent study by Towards Healthcare, the life science tools market size was valued at USD 111.28 billion in 2022 and is poised to exceed USD 367.16 billion by 2032, expanding at a CAGR of 13% between 2023 and 2032.

89bio, Inc. announced the appointment of Martin Babler to its Board of Directors, effective April 13, 2024.

NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the first quarter of 2024 after market close on Wednesday, May 8, 2024.

Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the first quarter 2024 after market close on Tuesday, May 7, 2024.

Serina Therapeutics, Inc., a clinical-stage biotechnology company focused on developing its proprietary POZ PlatformTM drug delivery technology announced the appointment of Dr. Simba Gill as Executive Chairman.

Global Cell-Free RNA Isolation & Extraction Kits Market is valued at US$ 41.55 Mn in 2023, and it is expected to reach US$ 123.94 Mn by 2031, with a CAGR of 14.90% during the forecast period of 2024-2031.

Biohaven Ltd. announced that it has commenced an underwritten public offering of $200 million of its common shares.